<span item_type="fundamental" item_id="b39e04b0ffecb4febd1c5b120cba82c8" counter_id="ST/US/MDRX" env="prod"></span><span item_type="announcement" item_id="652724160972588673" env="prod"></span><p>Revenue: As of FY2024, the actual value is USD 594.4 M.</p><p>EPS: As of FY2024, the actual value is USD -2.7.</p><p></p><h4>Historical Financial Performance (2024 vs. 2023)</h4><h4>Total Revenue</h4><p>Allscripts 医疗 (Veradigm Inc.) reported total revenue of $594.4 million in 2024, a decrease from $626.0 million in 2023, with the 2023 revenue including $19.0 million of non-recurring revenue from settlements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></p><h4>Segment Revenue</h4><ul><li>Provider Segment Revenue was $473.1 million in 2024, down from $492.1 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li><li>Payer Segment Revenue was $67.3 million in 2024, decreasing from $72.3 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li><li>Life Science Segment Revenue stood at $54.0 million in 2024, a decline from $61.6 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li></ul><h4>Net Income (Loss)</h4><p>Allscripts 医疗 (Veradigm Inc.) reported a Net Loss of - $291.6 million in 2024, compared to Net Income of $49.2 million in 2023, primarily due to an impairment of goodwill and other assets, as well as transaction and other costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></p><h4>Adjusted EBITDA</h4><p>Adjusted EBITDA was $94.1 million in 2024, a decrease from $131.5 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span>Adjusted EBITDA Margin was 15.8% in 2024, down from 21.7% in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></p><h4>Gross Profit and Margin (GAAP)</h4><p>Gross Profit was $302.2 million in 2024, a decline from $341.5 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span>Gross Margin was 50.8% in 2024, down from 54.6% in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></p><h4>Operating Expenses</h4><ul><li>Selling, general and administrative expenses were $269.4 million in 2024, an increase from $200.9 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li><li>Research and development expenses totaled $108.3 million in 2024, up from $97.0 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li><li>Impairment of goodwill and other assets was $108.2 million in 2024, significantly higher than $0.2 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li><li>Amortization of intangibles was $11.0 million in 2024, an increase from $8.7 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li></ul><h4>Income (Loss) from Operations</h4><p>Allscripts 医疗 (Veradigm Inc.) reported Income (loss) from operations of - $194.7 million in 2024, compared to $34.7 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></p><h4>Balance Sheet Highlights (as of December 31)</h4><ul><li>Cash and cash equivalents were $294.3 million in 2024, down from $446.6 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li><li>Total Assets decreased to $1,352.3 million in 2024 from $1,572.9 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li><li>Total Liabilities increased to $548.3 million in 2024 from $498.4 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li><li>Total Stockholders’ Equity was $804.0 million in 2024, a decrease from $1,074.5 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li><li>Long-term debt was $72.2 million in 2024, compared to $0.0 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></li></ul><h4>Cash Flow</h4><p>Operating cash flow and free cash flow data were not provided in the reference for historical performance.</p><h4>Outlook / Guidance</h4><p>Allscripts 医疗 (Veradigm Inc.) anticipates its 2026 full-year revenue will improve due to a more focused product and platform strategy, with profitability positively influenced by AI-specific investments and cost actions initiated in fall 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span> For 2025, the company estimates total revenue to be in the range of $584 million to $589 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span> Additionally, Net Cash is projected to be $45 million by year-end December 31, 2025, consisting of $120 million in cash and cash equivalents and $75 million in debt.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1124804/000119312526239289/mdrx-ex99_1.htm"></span></p>

Veradigm | 8-K: FY2024 Revenue: USD 594.4 M